cilastatin has been researched along with Bacterial Infections, Gram-Negative in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (35.71) | 18.2507 |
| 2000's | 4 (28.57) | 29.6817 |
| 2010's | 3 (21.43) | 24.3611 |
| 2020's | 2 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Claeys, KC; Rybak, JM; Smith, JR | 1 |
| Heo, YA | 1 |
| Akers, W; Brown, ML; Du, J; Kartsonis, NA; Lee, YC; Mariyanovski, V; McLeroth, P; Paschke, A; Pedley, A; Sims, M | 1 |
| Advincula, MR; McLaughlin, MM; Miglis, C; Scheetz, MH; Skoglund, E; Wagner, J | 1 |
| Cizmeci, Z; Dereli, N; Günay, E; Küçükbayrak, A; Uğurman, F | 1 |
| Badal, RE; Boffard, KD; Botha, RF; Brink, AJ; Feldman, C; Grolman, DC; Joubert, I; Poswa, X; Pretorius, J; Richards, GA; Senekal, M; Veller, M | 1 |
| Ikeya, M; Ryo, E; Sugimoto, M | 1 |
| Archontoulis, N; Giamarellos-Bourboulis, EJ; Giamarellou, H; Mega, A; Pavleas, I; Rigas, K; Thomopoulos, G; Vernikos, P | 1 |
| Bonnaure-Mallet, M; Jolivet-Gougeon, A; Sixou, JL; Tamanai-Shacoori, Z | 1 |
| Domon, H; Furuya, N; Ishii, K; Matsumoto, T; Miyazaki, S; Ohno, A; Tateda, K; Yamaguchi, K | 1 |
| Geddes, A; Härkönen, M; Jacobs, F; Nowotny, I; Schonwald, S; Thaler, M | 1 |
| Benedetto, G; Enrichens, F; Franchello, A; Mao, P; Olivero, G; Olivero, S; Sciascia, C | 1 |
| Cruz, C; del Busto, R; Faber, MD; Mezger, E | 1 |
| Sesin, GP | 1 |
3 review(s) available for cilastatin and Bacterial Infections, Gram-Negative
| Article | Year |
|---|---|
Imipenem-Cilastatin-Relebactam: A Novel β-Lactam-β-Lactamase Inhibitor Combination for the Treatment of Multidrug-Resistant Gram-Negative Infections.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Cilastatin; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Imipenem; Microbial Sensitivity Tests | 2020 |
Imipenem/Cilastatin/Relebactam: A Review in Gram-Negative Bacterial Infections.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamase Inhibitors; beta-Lactamases; Cilastatin; Drug Combinations; Gram-Negative Bacterial Infections; Humans; Imipenem; Injections, Intravenous | 2021 |
Antimicrobial treatment of Capnocytophaga infections.
Topics: Animals; Anti-Bacterial Agents; Bacteremia; beta-Lactam Resistance; beta-Lactamases; beta-Lactams; Capnocytophaga; Cilastatin; Clindamycin; Endocarditis, Bacterial; Gram-Negative Bacterial Infections; Humans; Imipenem; Immunocompromised Host; Microbial Sensitivity Tests | 2007 |
5 trial(s) available for cilastatin and Bacterial Infections, Gram-Negative
| Article | Year |
|---|---|
Prospective, randomized, double-blind, Phase 2 dose-ranging study comparing efficacy and safety of imipenem/cilastatin plus relebactam with imipenem/cilastatin alone in patients with complicated urinary tract infections.
Topics: Administration, Intravenous; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamase Inhibitors; Cilastatin; Cilastatin, Imipenem Drug Combination; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Female; Gram-Negative Bacterial Infections; Humans; Imipenem; Male; Middle Aged; Prospective Studies; Pyelonephritis; Urinary Tract Infections; Young Adult | 2017 |
Clinical study of the effectiveness of imipenem/cilastatin sodium as the antibiotics of first choice in the expectant management of patients with preterm premature rupture of membranes.
Topics: Adult; Anti-Bacterial Agents; Cilastatin; Female; Fetal Membranes, Premature Rupture; Gestational Age; Gram-Negative Bacterial Infections; Gram-Positive Bacterial Infections; Humans; Imipenem; Infant, Newborn; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Outcome; Pregnancy Trimester, Third | 2005 |
Impact of carbapenem administration on systemic endotoxemia in patients with severe sepsis and Gram-negative bacteremia.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacteremia; C-Reactive Protein; Carbapenems; Cilastatin; Cilastatin, Imipenem Drug Combination; Drug Combinations; Endotoxemia; Female; Gram-Negative Bacterial Infections; Humans; Imipenem; Interleukin-6; Lipopolysaccharides; Male; Middle Aged; Pneumonia, Ventilator-Associated; Sepsis | 2006 |
Levofloxacin in the empirical treatment of patients with suspected bacteraemia/sepsis: comparison with imipenem/cilastatin in an open, randomized trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Bacteremia; Cilastatin; Cilastatin, Imipenem Drug Combination; Drug Combinations; Drug Therapy, Combination; Gram-Negative Bacterial Infections; Gram-Positive Bacterial Infections; Humans; Imipenem; Levofloxacin; Middle Aged; Ofloxacin; Protease Inhibitors; Sepsis; Thienamycins | 1999 |
Imipenem-cilastatin in the treatment of hospital infections.
Topics: Cilastatin; Cross Infection; Drug Therapy, Combination; Gram-Negative Bacterial Infections; Humans; Imipenem; Prognosis; Protease Inhibitors; Thienamycins; Treatment Outcome | 1991 |
6 other study(ies) available for cilastatin and Bacterial Infections, Gram-Negative
| Article | Year |
|---|---|
Effect of elevated imipenem/cilastatin minimum inhibitory concentrations on patient outcomes in Gram-negative bloodstream infections.
Topics: Aged; Bacteremia; Cilastatin; Drug Resistance, Bacterial; Female; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Imipenem; Male; Microbial Sensitivity Tests; Middle Aged; Retrospective Studies; Treatment Outcome | 2018 |
[A community acquired pneumonia case caused by Ralstonia pickettii].
Topics: Anti-Bacterial Agents; Cilastatin; Cilastatin, Imipenem Drug Combination; Community-Acquired Infections; Drug Combinations; Gram-Negative Bacterial Infections; Humans; Imipenem; Male; Middle Aged; Opportunistic Infections; Pneumonia, Bacterial; Protease Inhibitors; Pulmonary Disease, Chronic Obstructive; Ralstonia pickettii; Treatment Outcome | 2009 |
Antimicrobial susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in South African hospitals (SMART Study 2004-2009): impact of the new carbapenem breakpoints.
Topics: Anti-Bacterial Agents; Carbapenems; Cilastatin; Cilastatin, Imipenem Drug Combination; Drug Combinations; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Imipenem; Intraabdominal Infections; Microbial Sensitivity Tests; Prevalence; South Africa | 2012 |
In vitro and in vivo antibacterial activities of CS-834, a new oral carbapenem.
Topics: Animals; Carbapenems; Cilastatin; Drug Resistance, Microbial; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Humans; Male; Mice; Mice, Inbred ICR; Microbial Sensitivity Tests; Prodrugs; Protease Inhibitors; Sepsis | 1998 |
Response of Weeksella virosa peritonitis to imipenem/cilastin.
Topics: Adult; Anti-Bacterial Agents; Cilastatin; Cilastatin, Imipenem Drug Combination; Drug Combinations; Female; Gram-Negative Bacterial Infections; Humans; Imipenem; Peritoneal Dialysis, Continuous Ambulatory; Peritonitis | 1991 |
Imipenem/cilastatin drug utilization evaluation in a large community hospital.
Topics: Adult; Anti-Bacterial Agents; Cilastatin; Cilastatin, Imipenem Drug Combination; Drug Combinations; Drug Utilization; Evaluation Studies as Topic; Female; Gram-Negative Bacterial Infections; Hospitals, Community; Humans; Imipenem; Male; Middle Aged | 1991 |